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Key words: composition, fatty acids, LDL, nutrition, olive oil, poliphenols, oxidative markers
Objective: The aim of our study was to assess the changes in the fatty acid composition of low density
lipoproteins (LDL) after sustained consumption of olive oil at real-life doses (25 mL/day) and their relationship
with lipid oxidative damage.
Methods: A multi-center randomized, cross-over, clinical trial with 3 similar types of olive oils, but with
differences in the phenolic content, was conducted on 200 healthy European subjects. Intervention periods were
of 3 weeks separated by 2-week washout periods. The LDL fatty acid content was measured in samples drawn
at baseline and after the last intervention period.
Results: After olive oil ingestion oleic acid concentration in LDL increased (1.9%; p  0.001) and those of
linoleic (1.1%; p  0.002) and arachidonic acid (0.5%; p  0.001) decreased. Monounsaturated/polyunsaturated
fatty acid and oleic/linoleic acid ratios in LDL increased after olive oil consumption. An inverse relationship
between the oleic/linoleic acid ratio and biomarkers of oxidative stress was observed. One unit increase in the
oleic/linoleic acid ratio was associated with a decrease of 4.2 g/L in plasma isoprostanes.
Conclusion: Consumption of olive oil at real-life doses improved the fatty acid profile in LDL, the changes
being associated with a reduction of the oxidative damage to lipids.
INTRODUCTION
The Mediterranean diet is considered to be a protective factor
in the primary and secondary prevention of coronary heart disease
(CHD) [1,2], and against oxidative stress associated processes
[3,4]. This protection has been related to the relatively high con-
tent in this diet of non hydrogenated, monounsaturated fatty acids
(MUFA) [5,6], since olive oil is the main source of fat in the
Mediterranean diet [1]. The predominant fatty acid in olive oil is
the MUFA oleic acid (18:1, n-9) with percentages ranging from
56% to 84%, while the polyunsaturated fatty acid (PUFA)
linoleic acid (18:2, n-6) is usually found at percentages between
3% and 21% [7]. However, olive oil also contains several
minor components with potentially healthy biological proper-
ties [7]. Several mechanisms have been proposed to explain the
preventive effects of olive oil on atherosclerosis development.
Among them, the reduction of the low-density lipoprotein
(LDL) susceptibility to oxidation has been one of the main
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mechanisms addressed. Consequences of this reduction are a
protection on cellular oxidative stress, thrombogenicity, and
atheroma plaque formation [8,9].
In the frame of the EUROLIVE study we have previously
reported an increase in plasma fatty acids after olive oil con-
sumption [10]. However, contradictory data have been reported
about the effects of olive oil (and its main components) on
lipoprotein metabolism: some authors report that olive oil sup-
plementation did not modify LDL fatty acid composition
[11,12]. In contrast, an increase in the oleic acid incorporation
to LDL after olive oil consumption has been reported in hu-
mans [13,14] and in animal studies [15–17]. In some of these
studies [15] a decrease in the LDL oxidability was observed
together with an increase in oleic acid in LDL. Data from these
studies are difficult to interpret because, in most of them, olive
oil was ingested as a dietary supplement, nor in replacement of
other fats [18–20]. To the best of our knowledge, there are no
studies with a large sample size in which the effect of olive oil
ingestion on fatty acid LDL composition has been examined. In
this context, the aim of the present study, based on data from
the Eurolive Study (5th EU-Framework Program) [21], is to
assess the effect of olive oil on the LDL fatty acid content and
its relationship with plasma oxidation markers in a large sample
of healthy European male adults.
MATERIALS AND METHODS
Study Design and Study Population
The EUROLIVE study [21] was a randomized, crossover
trial with three intervention periods of three weeks and two
wash-out periods of 2 weeks. Three types of olive oils with
high (HPC, 366 mg/Kg), medium (MPC, 164 mg/Kg), and low
(LPC, 2.7 mg/Kg) phenolic content were used. Olive oils were
specially prepared for the trial from an extra virgin olive oil
(produced from Picual olives, Spain) as it follows: a virgin
olive oil with a high natural phenolic content (366 mg/kg) was
selected. Fatty acid and vitamin E composition were measured.
Harvests of this type of virgin olive oil, from the same cultivar
and soil, which were submitted to refinement, were tested in
order to choose one with a similar fatty acid and micronutrient
profile to that of the virgin olive oil selected. An adjustment of
vitamin E to similar values of that present in the virgin olive oil
selected was performed. Phenolic compounds are lost in the
refination process, due to this, the refined olive oil had a low
phenolic content (2.7 mg/kg). By mixing virgin and refined
olive oil, an olive oil with an intermediate phenolic content
(164 mg/kg) was obtained. Finally, the three oils had similar fat
and micronutrient (i.e. vitamin E, triterpenes, sitosterols) com-
position, but with relevant differences only in their phenolic
content (Table 1) [14]. Fatty acid composition was determined
by gas chromatography [22].
We enrolled 200 healthy European males (mean age: 33.1 
10.6 years) recruited from September 2002 through June 2003
in 6 Centers of 5 European Countries (Denmark, Finland,
Germany, Italy, and Spain). Eligibility criteria were a willing-
ness to provide written, informed consent and to agree to
adhere to the protocol. Exclusion criteria were: smoking, intake
of antioxidant supplements, aspirin, or drugs with established
antioxidant properties, hyperlipidemia, obesity (body mass in-
dex 30 kg/m2), diabetes, hypertension, celiac or other intes-
tinal disease, any condition limiting mobility, life-threatening
diseases, or any other disease or condition that could impair
compliance. Subjects were considered healthy on the basis of
physical examination and routine biochemical and hematolog-
ical laboratory determinations. The protocol was approved by
the Ethics Committee of each Clinical Trial Center involved.
Olive oils were sequentially administered over three periods
of 3 weeks preceded by two-week wash-out periods in which
participants were requested to avoid olive oil and olive con-
sumption. In intervention periods, subjects were provided with
25 mL/day of olive oil, administered among meals. Participants
were requested to avoid a high intake of foods listed as con-
taining antioxidants. Participants recorded their habitual diet on
diet records during three consecutive days at baseline and the
end of the study period. Participants were personally advised by
a nutritionist on how to record food consumption and follow
the above mentioned dietary recommendations. Food consump-
tion was converted into the corresponding nutrient intake by
means of a validated nutrition software from each country.
Physical activity was recorded at baseline and at the end of the
study [23]. The full protocol has been previously and fully
described elsewhere [21].
Table 1. Characteristics of the Olive Oils Administered
Type of olive oil
LPC MPC HPC
Quality parameters
Free acidity (% oleic acid) 0.03 0.08 0.18
Peroxide value (mEq O2/kg) 4.12 5.89 11.28
Fatty acids (%)
C14:0 0.01 0.01 0.01
C16:0 10.63 10.50 10.63
C16:1 0.88 0.86 0.88
C17:0 0.05 0.05 0.04
C17:1 0.09 0.09 0.09
C18:0 3.27 3.13 2.84
C18:1 79.08 79.80 80.60
C18:2 4.64 4.21 3.35
C20:0 0.39 0.39 0.35
C18:3 0.58 0.58 0.58
C20:1 0.26 0.25 0.25
C22:0 0.11 0.10 0.10
C24:0 0.01 0.02 0.02
-Tocopherol (ppm) 229 228 228
Phenolic compounds (ppm) 2.7 164 366
Squalene (mg/g) 3.0 3.2 3.4
-sitosterol (mg/g) 1.4 1.5 1.5
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For the present study we used data of the baseline and the
endpoint (last intervention). Serum glucose, total cholesterol (TC),
high-density lipoprotein cholesterol (HDL-C), and triacylglycerols
(TG) were determined by standardized enzymatic methods. LDL
cholesterol was calculated by the Friedewald formula. Plasma
circulating oxidized LDL (oxLDL) was measured by enzimo-
immunoassay. Plasma total F2-isoprostanes were determined us-
ing high performance liquid chromatography and stable isotope
dilution mass spectrometry [24]. Serum LDL uninduced conju-
gated dienes (CD) were measured by spectrophotometry at 234
nm and 300 nm. CD concentration was adjusted for the cholesterol
concentration in LDL. LDL isolation was performed by sequential
flotation ultracentrifugation from plasma EDTA samples [21]. The
fatty acid composition of the isolated LDL was determined fol-
lowing the method described by Bondı́a et al. [25] in which fatty
acids are transformed into methyl esters and analyzed by gas
chromatography. Apolipoprotein B in LDL was measured by
immunoturbidimetry. Fatty acids were expressed as mg/g of LDL-
apolipoprotein B100. All determinations were centralized in ref-
erence laboratories.
Statistical Analyses
Baseline data are shown as mean  SD and 5% trimmed
mean values. Kolmogorov Smirnov test and normal probability
plots were used to assess normal distribution. One-factor
ANOVA and Kruskal-Wallis test were used to determine dif-
ferences in basal characteristics and nutrient intake among the
three olive oil interventions. A Student’s t test for paired
samples was used to compare LDL fatty acid composition at
baseline and at the end of the intervention.
Multiple regression models were fitted in order to evaluate
the association between oxidative markers and fatty acids in
LDL. These models used the oxidative markers postinterven-
tion values, adjusted by basal values, as dependent variable and
the difference in the oleic/linoleic ratio in LDL as independent
variable. For the plasma isoprostanes model, arachidonic acid
in LDL was also included as an adjusting variable. Because
there was no interaction with the olive oil administration order,
it was not included in the models. Statistical significance was
defined as p  0.05 for a two-sided test. All tests were per-
formed using the SPSS System for Windows release 11.0.
RESULTS
Eighteen participants (9%) did not complete the study. No
one relevant side effect was registered during the research. At
the beginning of the study, 193 (96.5%) participants submitted
food records. Mean total energy intake was 2261 calories daily,
with 48.6%, 33.8%, and 15.8% of calories derived from car-
bohydrate, fat, and protein, respectively. Table 2 shows the
mean nutrient intake, at the beginning and at the end of the
study. Mean total energy intake was unchanged. There was a
significant increase in fat intake from the beginning to the end
of the study (mean values, 86.4 g/day versus 95.1 g/day, p 
0.005), mainly linked to the increase of MUFA (mean values,
30.9 g/day versus 39.8 g/day, p  0.001) as oleic acid (mean
values, 27.5 g/day versus 34.8 g/day). Polyunsaturated (PUFA)
and saturated fat (SFA) intake remained constant. Consumption
of carbohydrates decreased (3.3% as average, p  0.001),
while alcohol and protein intake did not change.
Plasma total and LDL cholesterol did not change. HDL
cholesterol (p  0.001) and glucose (p  0.05) increased,
whereas F2-isoprostanes decreased (p  0.01). Lipid values
and oxidative stress markers before and after interventions are
shown in Table 3.
The fatty acid composition of LDL expressed as an absolute
value in mg/g of LDL-apolipoprotein B100 and as a percentage
of fatty acids is shown in Table 4. The Kolmogorov-Smirnov
test demonstrates that the main LDL fatty acids have a baseline
distribution that is not normal: the Q-Q plots between expected
and observed values show that the overlapping area between
the expected “normal” distribution and that observed is very
high, but in two tails some values are markedly higher or lower
than expected. In the hypothesis that these outliers represent
subjects with peculiar characteristics, we also repeated com-
parative analyses with 5% trimmed means.
A significant enrichment of oleic acid (C18:1 n-9) in LDL
was observed (p  0.001). MUFA/PUFA and oleic/linoleic
acid ratios in LDL increased. When considering the LDL
percent content of fatty acids, oleic acid increased (p  0.001),
and linoleic and arachidonic acid decreased (p  0.005). No
changes were observed in the percentage of palmitic and stearic
acids. When paired comparisons in absolute values obtained at
the end of the study were examined, olive oil administration
increased significantly oleic acid in LDL (p  0.001). When
differences were adjusted for energy intake and order of olive
oil administration, the comparisons described above remained
significant. The significance of the association was maintained
when stratifying by center.
Isoprostanes were inversely correlated with the difference in
the oleic/linoleic ratio: for every increase of 1 mg/g in the oleic/
linoleic ratio, F2-isoprostanes decreased by 4.2 g/L. There was
no relationship between adjusted isoprostanes and difference in
arachidonic acid between interventions. F2-isoprostanes, adjusted
by baseline levels, were, however, directly related with levels of
arachidonic acid after olive oil consumption (B  0.024, 95% CI
0.002–0.046; p  0.030). The overall model, with difference in
oleic/linoleic ratio age and arachidonic acid in LDL simulta-
neously as independent variables, explains a 7.6% of the isopros-
tane variation (r  0.276, p  0.004). The difference in the
oleic/linoleic ratio is being the variable with the strongest relation-
ship to isoprostanes (Table 5). Further adjustments by other co-
variates (such as. energy intake, change in fat intake from baseline,
and olive oil administration sequence) did not modify the trend.
No relationship was observed with the other variables, including
uninduced dienes.
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DISCUSSION
In this study, sustained consumption of olive oil, in replace-
ment of other fats, at a real life dose of 25 mL per day,
increased the oleic acid content of the LDL as well as the
MUFA/PUFA and oleic/linoleic acid ratios in LDL. Changes in
the LDL fatty acid composition were inversely related with
oxidative lipid and LDL damage. These results were indepen-
dent of the type of olive oil consumed.
Higher MUFA intake has been associated with a more favor-
able cardiovascular risk profile [26]. In our study, carbohydrate
consumption decreased with the increase in olive oil consumption.
Low carbohydrate/high fat diets typically increase HDL choles-
terol levels versus high carbohydrate/low fat diets [27–29]. In
agreement with this, and with our previous results [10,21,30], we
observed an increase in serum HDL-cholesterol after olive oil
ingestion. Benefits of olive oil consumption on the lipid profile
were also reflected in the reduction of total/HDL cholesterol and
Table 2. Dietary Intake Characteristics, as Mean Nutrient Intake and Differences, at the Beginning and at the End of the Study
Component (g) Mean SD Absolute change p value
Carbohydrates baseline 275.8 91.1
end 256.9 84.4 18.8 0.001
Protein baseline 88.7 27.5 3.1 0.137
end 85.5 26.8 3.1 0.137
Total fat baseline 86.4 30.6
end 95.1 34.6 8.6 0.002
SFA baseline 33.7 15.4
end 32.6 14.6 1.1 0.360
MUFA baseline 30.9 12.6
end 39.8 16.1 8.9 0.001
PUFA baseline 12.1 6.2
end 12.3 6.0 0.2 0.630
Cholesterol (mg) baseline 329.7 149.5
end 310.9 151.6 13.5 0.243
Oleic acid baseline 27.5 11.3
end 34.8 15.1 7.3 0.001
Alcohol baseline 81.0 191.0
end 74.3 191.0 6.7 0.292
% Kcal
Energy (Kcal) baseline 2275.3 654.3
end 2366.3 1258.8 91.0 0.302
Carbohydrates baseline 48.5 8.2
end 45.2 9.4 3.3 0.001
Protein baseline 16.0 3.9
end 15.2 3.6 0.8 0.020
Total fat baseline 34.1 6.9
end 37.5 10.3 3.4 0.001
SFA baseline 13.0 3.7
end 12.6 3.5 0.4 0.207
MUFA baseline 12.3 4.0
end 15.9 5.9 3.6 0.001
PUFA baseline 4.8 2.1
end 4.8 1.9 0.0 0.902
Saturated fat  SFA, monounsaturated fat  MUFA, polyunsaturated fat  PUFA.
Table 3. Lipid Values and Oxidative Stress Markers at the Beginning and at the End of the Study
Base line End
p
Mean DS Mean DS
Cholesterol (mg/dL) 182.7 40.2 184.4 42.1 ns
Triacylglycerols (mg/dL) 95.6 49.0 91.4 44.5 ns
HDL cholesterol (mg/dL) 47.3 11.1 50.5 12.6 0.001
LDL cholesterol (mg/dL) 116.5 36.7 115.7 38.2 ns
Glucose (mg/dL) 85.7 9.7 87.3 10.8 0.035
Oxidized LDL (U/L) 49.4 22.8 47.2 22.4 ns
Serum-LDL uninduced conjugated dienes (umol/mmol cholesterol) 11.8 3.5 11.7 3.8 ns
Plasma-F2-isoprostanes (ng/L) 29.2 6.7 28.0 6.9 0.01
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LDL/HDL cholesterol ratios. The total/HDL cholesterol ratio is an
established and efficient indicator of lipid atherogenesis, reflecting
the balance of cholesterol transport in and out of the arterial intima
[31]. In a recent report with data from the 20-year follow up
Framingham Offspring Study, total/HDL cholesterol and LDL/
HDL cholesterol ratios have been reported to be the most efficient
lipid parameters for predicting CHD [32].
We also observed a decrease in F2-isoprostanes from the
beginning to the end of the study. In a previous work [21] we
did not observe statistically significant differences in this oxi-
dative biomarker when comparing values before and after each
one of the three olive oil intervention periods. The fact that
significant changes in F2-isoprostanes were observed after sev-
eral periods of olive oil consumption suggests, despite the fact
that no carryover was detected in the washout periods [21], that
a long-term consumption of olive oil is required to observe
changes in F2-isoprostane plasma concentrations.
Dietary fat can modulate the susceptibility of LDL to oxi-
dative modification. Most studies comparing the effect of a
MUFA-rich diet with that of a PUFA-rich one concluded that
MUFA-rich diets reduced the susceptibility of LDL to oxida-
tion [33]. Thus, oleate rich LDL appeared to be more resistant
to oxidation than linoleate-enriched LDL. Oxidation of the
lipids and lipoproteins present in LDL leads to a change in the
lipoprotein conformation by which LDL is better able to enter
the monocyte/macrophage system of the arterial wall, and
promote the atherosclerotic process [34]. After olive oil con-
sumption the susceptibility of LDL to oxidation, however,
depends not only on the change in the LDL fatty acid content
promoted by olive oil, but also on the phenolic content bound
to the LDL. Recent results of the EUROLIVE study [21] have
provided evidence of the protective role of phenolic com-
pounds from olive oil on the in vivo LDL oxidation in humans.
Olive oil phenolic compounds have also been shown to mod-
ulate the LDL phenolic content and the in vivo LDL oxidation
at postprandial state in humans [35]. In the present study, we
observed a reduction of the in vivo LDL oxidative damage
associated with an enrichment of oleic acid in LDL after
sustained olive oil consumption. However, the decrease in the
degree of the in vivo LDL oxidation from the baseline to the
end of the study did not reach significance. The differences
among the olive oil phenolic content ingested in the last inter-
vention period could account for this fact.
In our study, we also observed an inverse relationship
between the oleic/linoleic acid ratio in LDL and the plasma
concentration of isoprostans. Plasma F2-isoprostanes are con-
sidered to be a systemic marker of oxidative stress [36] and
high levels of circulating F2-isoprostanes have been shown to
be predictors of cardiac events in CHD patients [36]. The
increase in the oleic/linoleic acid ratio in LDL has been shown
to promote favorable changes in inflammatory markers. Tsimi-
kas et al [37] observed that an increase in the oleic/linoleic acid
ratio in LDL induced less monocyte chemotaxis and adhesion
when exposed to oxidative stress.
In summary, real-life daily doses of olive oil (25 mL/day)
increased oleic acid and the oleic/linoleic acid ratio in LDL and
improved the cardiovascular risk lipid profile. This increase in




Mean SD 5% trimmed mean Mean SD 5% trimmed mean
Oleic mg/gApo B 100 147.30 74.82 140.61 166.66** 80.12 160.48
% 21.12 2.66 21.09 22.99** 2.81 22.96
Linoleic mg/gApo B 100 303.29 150.82 293.01 312.62 156.19 302.50
% 43.24 4.90 43.33 42.22* 4.41 42.36
Palmitic mg/gApo B 100 144.72 75.24 137.86 150.80 74.39 144.70
% 20.78 2.70 20.83 20.56 2.18 20.47
Stearic mg/gApo B 100 48.07 23.27 46.11 49.71 24.80 47.73
% 7.00 1.46 6.85 6.83 1.63 6.64
Arachidonic mg/gApo B 100 54.65 31.14 51.68 53.85 27.42 51.85
% 7.86 1.18 7.80 7.39** 1.52 7.33
Oleic/linoleic ratio 0.50 0.14 0.55** 0.12
* p  0.01, ** p  0.001.
Table 5. Linear Regression Coefficients (Standard Error) of
the Relations between F2-Isoprostanes with Difference in
Oleic/Linoleic Ratio, Adjusted for Age and Arachidonic Acid
in LDL
F2-isoprostanes (g/L)
Change inoleic/linoleic (units) 4.208 (1.897)*
Age(year) 0.0520 (0.026)*
Arachidonic Acid in LDL




Change in oleic/linoleic ratio  difference in the oleic/linoleic ratio in LDL
between baseline and after olive oil consumption, Ox-LDL  oxidized LDL,
F2-isoprostanes  plasma F2-isoprostanes after olive oil ingestion.
* p  0.05, ** p  0.001.
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the oleic/linoleic acid ratio was inversely related with the
degree of lipid and LDL oxidation. Our study adds further
evidence to recommend the use of olive oil as a source of fat in
order to achieve benefits against classical and novel risk factors
of cardiovascular disease.
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